268 related articles for article (PubMed ID: 36952376)
21. Scope of Mathematical Biology in Cancer Research.
Raj AT; Patil S; Sarode SC; Sarode GS; Gadbail AR; Gondivkar S
J Contemp Dent Pract; 2018 Sep; 19(9):1035-1036. PubMed ID: 30287699
[TBL] [Abstract][Full Text] [Related]
22. Mathematical modeling of cancer: the future of prognosis and treatment.
Quaranta V; Weaver AM; Cummings PT; Anderson AR
Clin Chim Acta; 2005 Jul; 357(2):173-9. PubMed ID: 15907826
[TBL] [Abstract][Full Text] [Related]
23. Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy.
Enderling H; Alfonso JCL; Moros E; Caudell JJ; Harrison LB
Trends Cancer; 2019 Aug; 5(8):467-474. PubMed ID: 31421904
[TBL] [Abstract][Full Text] [Related]
24. Darwinian Approaches for Cancer Treatment: Benefits of Mathematical Modeling.
Belkhir S; Thomas F; Roche B
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503256
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Anscher MS; Chang E; Gao X; Gong Y; Weinstock C; Bloomquist E; Adeniyi O; Charlab R; Zimmerman S; Serlemitsos-Day M; Ning YM; Mayrosh R; Fuller B; Trentacosti AM; Gallagher P; Bijwaard K; Philip R; Ghosh S; Fahnbulleh F; Diggs F; Arora S; Goldberg KB; Tang S; Amiri-Kordestani L; Pazdur R; Ibrahim A; Beaver JA
Oncologist; 2021 Feb; 26(2):139-146. PubMed ID: 33145877
[TBL] [Abstract][Full Text] [Related]
26. Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes.
Hodgkinson A; Trucu D; Lacroix M; Le Cam L; Radulescu O
Front Oncol; 2022; 12():857572. PubMed ID: 35494017
[TBL] [Abstract][Full Text] [Related]
27. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
28. [Current problems in surgical oncology: 1. Theoretical models in oncology and their implications in surgical therapy].
Vasilescu C
Chirurgia (Bucur); 2011; 106(1):17-22. PubMed ID: 21523955
[TBL] [Abstract][Full Text] [Related]
29. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
Trials; 2019 May; 20(1):294. PubMed ID: 31138292
[TBL] [Abstract][Full Text] [Related]
30. Towards predictive stochastic dynamical modeling of cancer genesis and progression.
Ao P; Galas D; Hood L; Yin L; Zhu XM
Interdiscip Sci; 2010 Jun; 2(2):140-4. PubMed ID: 20640781
[TBL] [Abstract][Full Text] [Related]
31. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
32. Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: efficacy in numbers?
Kronik N; Kogan Y; Schlegel PG; Wölfl M
J Immunother; 2012; 35(2):116-24. PubMed ID: 22306899
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
35. Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy.
Yoon N; Krishnan N; Scott J
J Math Biol; 2021 Oct; 83(5):47. PubMed ID: 34632539
[TBL] [Abstract][Full Text] [Related]
36. Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory.
Zhang L; Ma J; Liu L; Li G; Li H; Hao Y; Zhang X; Ma X; Chen Y; Wu J; Wang X; Yang S; Xu S
Crit Rev Oncol Hematol; 2023 Dec; 192():104192. PubMed ID: 37898477
[TBL] [Abstract][Full Text] [Related]
37. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
[TBL] [Abstract][Full Text] [Related]
38. Introduction: Cancer Gene Networks.
Clarke R
Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
Brady-Nicholls R; Nagy JD; Gerke TA; Zhang T; Wang AZ; Zhang J; Gatenby RA; Enderling H
Nat Commun; 2020 Apr; 11(1):1750. PubMed ID: 32273504
[TBL] [Abstract][Full Text] [Related]
40. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE; Schoenfeld AJ; Makhnin A; Tobi Y; Wang Y; Frisco-Cabanos H; Chakrabarti S; Shi M; Napoli C; McDonald TO; Tan W; Hata A; Weinrich SL; Yu HA; Michor F
Nat Commun; 2021 Jun; 12(1):3697. PubMed ID: 34140482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
